Illusion of Reperfusion Does Anyone Achieve Optimal Reperfusion During Acute Myocardial Infarction?
暂无分享,去创建一个
[1] J. Hsia,et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.
[2] E. Topol,et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. , 1987, The New England journal of medicine.
[3] H. Gold,et al. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. , 1990, Circulation.
[4] R. Kloner,et al. Deleterious Effects of Oxygen Radicals in Ischemia/Reperfusion Resolved and Unresolved Issues , 1989, Circulation.
[5] A. DeMaria,et al. A Prospective, Randomized Trial Comparing Combination Half‐Dose Tissue‐Type Plasminogen Activator and Streptokinase With Full-Dose Tissue‐Type Plasminogen Activator , 1991, Circulation.
[6] A. Buda,et al. Effect of coronary reocclusion after initial reperfusion on ventricular function and infarct size. , 1991, Journal of the American College of Cardiology.
[7] F. Markwardt,et al. Antithrombotic Effects of Recombinant Hirudin in Experimental Angioplasty and Intravascular Thrombolysis , 1990, Thrombosis and Haemostasis.
[8] F. Dunn,et al. Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction , 1990, The Lancet.
[9] Y. Uchida,et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. , 1992, Science.
[10] J. Lowe,et al. The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.
[11] Brain Wr,et al. Mind and matter. , 1951 .
[12] T. Drake. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction , 1985 .
[13] E. Topol,et al. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. , 1994, Circulation.
[14] E. Falk,et al. Coronary thrombosis: pathogenesis and clinical manifestations. , 1991, The American journal of cardiology.
[15] E. Topol,et al. Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome. , 1988, American heart journal.
[16] E J Topol,et al. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. , 1990, Circulation.
[17] R. Virmani,et al. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation. , 1989, Circulation.
[19] F. Werf. DISCREPANCIES BETWEEN THE EFFECTS OF CORONARY REPERFUSION ON SURVIVAL AND LEFT VENTRICULAR FUNCTION , 1989, The Lancet.
[20] B. Coller. Platelets and thrombolytic therapy. , 1990, The New England journal of medicine.
[21] R. Califf,et al. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. , 1992, Journal of the American College of Cardiology.
[22] J. Saffitz,et al. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. , 1989, Circulation.
[23] M. Friedman,et al. The pathogenesis of a coronary thrombus. , 1966, The American journal of pathology.
[24] J. M. van der Pol,et al. Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: results of the anistreplase reocclusion multicenter study (ARMS). , 1991, The American journal of cardiology.
[25] R. Kloner,et al. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. , 1974, The Journal of clinical investigation.
[26] K. Friedman,et al. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.
[27] R. Califf,et al. Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study. , 1989, The American journal of cardiology.
[28] Janice,et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. , 1989, The Journal of clinical investigation.
[29] R. Virmani,et al. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. , 1989, Circulation.
[30] M. Gottwik,et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). , 1988, Journal of the American College of Cardiology.
[31] H. Hod,et al. Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.
[32] R. Califf,et al. Evaluation of Combination Thrombolytic Therapy and Timing of Cardiac Catheterization in Acute Myocardial Infarction: Results of Thrombolysis and Angioplasty in Myocardial Infarction–Phase5 Randomized Trial , 1991, Circulation.
[33] M. Pfisterer,et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.
[34] A. Buda,et al. Streptokinase thrombolysis in experimental coronary artery thrombosis: pattern of reflow and effect of a stenosis. , 1984, International journal of cardiology.
[35] Harold T. Dodge,et al. Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .
[36] R. Capone,et al. Myocardial hemorrhage after coronary reperfusion in pigs. , 1978, The American journal of cardiology.
[37] S. Hanson,et al. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[38] G. FitzGerald,et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.
[39] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.
[40] H. Lambertz,et al. THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.
[41] E. Braunwald,et al. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.
[42] K. Lee,et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.
[43] D. Massel,et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.
[44] S. Chierchia,et al. Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilator therapy. , 1987, The New England journal of medicine.
[45] R. Shebuski,et al. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. , 1990, Circulation.
[46] A. M. Skene,et al. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.
[47] J. Willerson,et al. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. , 1988, Circulation.
[48] J. May,et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. , 1989, Circulation.
[49] R. Califf,et al. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. , 1988, Circulation.
[50] M. Simoons,et al. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). , 1992, Journal of the American College of Cardiology.
[51] J. Gore,et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. , 1991, Circulation.
[52] E. Topol,et al. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. , 1987, Journal of the American College of Cardiology.
[53] D. Allen,et al. Pathological changes after intravenous streptokinase treatment in eight patients with acute myocardial infarction. , 1989, British heart journal.
[54] F. Sheehan,et al. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial. , 1988, Circulation.
[55] C. Lau,et al. Effects of severity of the residual stenosis of the infarct-related coronary artery on left ventricular dilation and function after acute myocardial infarction. , 1992, Journal of the American College of Cardiology.
[56] K. Lee,et al. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. , 1988, Circulation.
[57] J. Spann,et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. , 1986, The American journal of cardiology.
[58] R. Califf,et al. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. , 1989, Circulation.
[59] E. Braunwald,et al. Myocardial reperfusion: a double-edged sword? , 1985, The Journal of clinical investigation.
[60] G. Schmid-Schönbein,et al. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. , 1986, The American journal of physiology.
[61] F. Dunn,et al. A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. , 1991, British heart journal.
[62] J. Anderson,et al. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction. , 1984, Circulation.
[63] A. Weyman,et al. The effect of late patency of the infarct-related coronary artery on left ventricular morphology and regional function after thrombolysis. , 1992, American heart journal.
[64] B. Chaitman,et al. Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. , 1992, Journal of the American College of Cardiology.
[65] C. Werter,et al. Aspirin Versus Coumadin in the Prevention of Reocclusion and Recurrent Ischemia After Successful Thrombolysis: A Prospective Placebo‐Controlled Angiographic Study Results of the APRICOT Study , 1993, Circulation.
[66] D. Chamberlain. Unanswered questions in thrombolysis. , 1989, The American journal of cardiology.
[67] M. Gotsman,et al. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. , 1985, The New England journal of medicine.
[68] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[69] Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.
[70] F. Van de Werf,et al. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.
[71] U. Tebbe,et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) , 1992, Journal of the American College of Cardiology.
[72] E. Topol,et al. Treatment of recurrent ischemia after thrombolysis and successful reperfusion for acute myocardial infarction: effect on in-hospital mortality and left ventricular function. , 1991, Journal of the American College of Cardiology.
[74] H. Hellstrom. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.
[75] J L Ritchie,et al. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. , 1985, The New England journal of medicine.
[76] J. Anderson,et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. , 1992, Journal of the American College of Cardiology.
[77] C. Dunwiddie,et al. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. , 1992, Circulation research.
[78] F. Van de Werf. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. , 1989, Lancet.
[79] P. J. Simpson,et al. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. , 1990, Circulation.
[80] C. Costantini,et al. Consequences of reperfusion after coronary occlusion. Effects on hemodynamic and regional myocardial metabolic function. , 1974, The American journal of cardiology.
[81] D. Morris,et al. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens. , 1990, Journal of the American College of Cardiology.
[82] D. Tate,et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.
[83] A. Kitabatake,et al. Lack of Myocardial Perfusion Immediately After Successful Thrombolysis: A Predictor of Poor Recovery of Left Ventricular Function in Anterior Myocardial Infarction , 1992, Circulation.
[84] G. A. Murphy,et al. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators. , 1992, Journal of the American College of Cardiology.
[85] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[86] K. Allman,et al. The unstable ST segment early after thrombolysis for acute infarction and its usefulness as a marker of recurrent coronary occlusion. , 1991, The American journal of cardiology.
[87] M Gent,et al. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. , 1989, Journal of the American College of Cardiology.
[88] J. Loscalzo,et al. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. , 1992, Circulation research.
[89] U. Tebbe,et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. , 1993, Journal of the American College of Cardiology.
[90] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .
[91] K. Lee,et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.
[92] H. Kantarjian,et al. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. , 1990, The American journal of medicine.
[93] T. Waterston. FLUIDS FOR DIARRHŒA IN YOUNG CHILDREN , 1977, The Lancet.
[94] H. White,et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. , 1987, The New England journal of medicine.
[95] R. W. Brower,et al. DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION , 1985, The Lancet.
[96] G. FitzGerald,et al. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[97] U. Tebbe,et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.
[98] E. Topol,et al. Present status of rescue coronary angioplasty: current polarization of opinion and randomized trials. , 1992, Journal of the American College of Cardiology.
[99] P. Armstrong,et al. Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group. , 1991, Journal of the American College of Cardiology.
[100] Aims Trial Study Group. EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL , 1988, The Lancet.
[101] H. Gold,et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. , 1988, Circulation.
[102] B. Sobel,et al. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. , 1988, Circulation.
[103] B. De Bruyne,et al. Cardiac tamponade early after thrombolysis for acute myocardial infarction: a rare but not reported hemorrhagic complication. , 1991, Journal of the American College of Cardiology.
[104] K. Lee,et al. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. , 1989, Circulation.
[105] E. B. Carlson,et al. Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase. , 1988, Circulation.
[106] S. Gardell,et al. Effective Thrombolysis Without Marked Plasminemia After Bolus Intravenous Administration of Vampire Bat Salivary Plasminogen Activator in Rabbits , 1991, Circulation.
[107] T. Bashore,et al. Catheterization/rescue angioplasty following thrombolysis (craft) study: Acute myocardial infarction treated with recombinant tissue plasminogen activator versus urokinase , 1991 .
[108] K. Swedberg,et al. Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. , 1991, American heart journal.
[109] S. Chierchia,et al. Prevention of myocardial infarction by very early treatment with intracoronary streptokinase. Some clinical observations. , 1984, The New England journal of medicine.
[110] R. W. Brower,et al. RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.